Cofttek holdings limited


ARRY380 (937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

Not Intended for Therapeutic Use. For research use only.

CAS: 937265-83-3 Category

ARRY380 (937265-83-3) Description:

ARRY-380 analog is an analog of ARRY-380. ARRY-380 is also know as Tucatinib, also known as Irbinitinib, and ONT-380, is a n orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. ErbB-2 inhibitor ARRY-380 selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.

ARRY380 (937265-83-3) Specifications:

Product Name ARRY380
Chemical Name Arry-380; 937265-83-3; Arry380; ARRY-380 Analog; ARRY-380 (analog ); UNII-H32S1659ED


Purity >98% (HPLC)
CAS Number 937265-83-3
Molecular Formula C29H27N7O4S
Molecular Weight 569.64 g/mol
Monoisotopic Mass 569.185 g/mol
InChi Code InChI=1S/C29H27N7O4S/c1-19-13-21(4-7-26(19)39-22-9-11-36-28(15-22)32-18-34-36)35-29-24-14-20(3-6-25(24)31-17-33-29)27-8-5-23(40-27)16-30-10-12-41(2,37)38/h3-9,11,13-15,17-18,30H,10,12,16H2,1-2H3,(H,31,33,35)
Form Powder
Color N/A
Solubility  Soluble in DMSO
Storage Temp.  -20°C
Shelf life >2 years if stored properly
Handling Dry, dark
Application selective HER2 inhibitor


RIDADR NONH for all modes of transport


  1. Estok, Thomas M.; Zaknoen, Sara L.; Mansfield, Robert K.; Lawhon, Tracy. (Tragara Pharmaceuticals, Inc., USA). Therapies for treating cancer using combinations of COX-2 inhibitors and anti-HER2(ErbB2) antibodies or combinations of COX-2 inhibitors and HER2(ErbB2) receptor tyrosine kinase inhibitors. PCT Int. Appl. (2009), 121pp. CODEN: PIXXD2 WO 2009042618 A1 20090402.
  2. Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, Broom RJ, Kakadia PM, Bohlander SK, Marshall E, Baguley BC.Front Oncol. 2018 Oct 12;8:425. doi: 10.3389/fonc.2018.00425. eCollection 2018.PMID: 30370249 Free PMC Article
  3. Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK.Clin Cancer Res. 2017 Jul 15;23(14):3529-3536. doi: 10.1158/1078-0432.CCR-16-1496. Epub 2017 Jan 4.PMID: 28053022 Free Article